Cardiac tamponade has increased as a complication of permanent pacemaker placement, although with small absolute numbers, a national study found.
The rate of in-hospital occurrence rose 35% from 0.26% in 2008 to 0.35% in 2012 among patients receiving permanent pacemakers, , of Rutgers New Jersey Medical School in Newark, and colleagues found.
In-hospital deaths for patients who developed tamponade rose as well over that 5-year span (5.2% versus 7.1%) in the study, published online in .
The authors noted a greater likelihood of cardiac tamponade in:
- Women (OR 1.23, 95% CI 1.04 to 1.54);
- Recipients of dual chamber pacemakers (OR 1.68, 95% CI 1.17 to 2.41); and
- Those with chronic liver disease (OR 3.18, 95% CI 1.92 to 5.64).
"These findings provide insight into the increasing burden of tamponade among patients receiving permanent pacemaker devices and helps physicians to identify patients at highest risk for development of in-hospital tamponade following the procedure," Waller and colleagues concluded.
The reported rise in effusion rates is "worrisome," although the absolute increase in the rate is "really very small," commented , of The Mount Sinai Hospital in New York City, who was not part of the investigation. "I'm not sure it impacts our practice that much."
Even so, "it was important that effusions were associated with a substantial increase in mortality," Reddy told MedPage Today. "While not proven to be causative, it is certainly suggestive. This again highlights the importance of trying to minimize the occurrence of effusions in clinical practice."
Also asked for his opinion, , of the Texas Tech University Health Sciences Center in El Paso, agreed that the incidence of in-hospital cardiac tamponade "is still low and not clinically significant."
"It would be helpful to know the number of single-chamber, dual-chamber, and biventricular pacers placed each year to ascertain whether this influenced the rising incidence of in-hospital cardiac tamponade," he told MedPage Today.
Reddy suggested other variables -- such as anticoagulation status and increased stenting -- that may have contributed to the increased rate over time.
Waller's group utilized the Nationwide Inpatient Sample for their study, accessing the records of 922,549 patients who received permanent pacemakers between 2008 and 2012.
Disclosures
Waller and Lange declared no relevant conflicts of interest.
Reddy disclosed consulting for Biotronik, Boston Scientific, Medtronic, and St. Jude Medical.
Primary Source
JACC: Clinical Electrophysiology
Moazzami K, et al "Trends in cardiac tamponade among recipients of permanent pacemakers in the United States: From 2008 to 2012" JACC Clin Electrophysiol 2016; DOI: 10.1016/j.jacep.2016.05.009.